Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
暂无分享,去创建一个
Marleen Keyaerts | Nick Devoogdt | Tony Lahoutte | Serge Muyldermans | S. Muyldermans | N. Devoogdt | T. Lahoutte | M. Keyaerts | J. Puttemans | A. Krasniqi | Yana Dekempeneer | Ahmet Krasniqi | Janik Puttemans | Matthias D’huyvetter | M. D'Huyvetter | Yana Dekempeneer
[1] R. Larsen,et al. Influence of pretreatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APB) on organ uptake of 211At and 125I-labeled amidobisphosphonates in mice. , 1999, Nuclear medicine and biology.
[2] A. Snyder,et al. Acquired resistance to immunotherapy and future challenges , 2016, Nature Reviews Cancer.
[3] D. Bigner,et al. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[4] D. Bigner,et al. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. , 1997, Nuclear medicine and biology.
[5] M. Brechbiel,et al. Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation. , 2015, AIMS medical science.
[6] P. Gisondi,et al. Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities , 2015, Front. Med..
[7] H. Lyerly,et al. N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. , 2014, Nuclear medicine and biology.
[8] Nick Devoogdt,et al. Preclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] J. Humm,et al. Targeted alpha particle immunotherapy for myeloid leukemia. , 2002, Blood.
[10] S. Larson,et al. Preparation of α-Emitting 213Bi-Labeled Antibody Constructs for Clinical Use , 1999 .
[11] M. Zalutsky,et al. No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. , 1995, Nuclear medicine and biology.
[12] S. Muyldermans,et al. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer , 2014, Expert opinion on drug delivery.
[13] T. Waldmann,et al. Effective Treatment of Established Human Breast Tumor Xenografts in Immunodeficient Mice with a Single Dose of the α-Emitting Radioisotope Astatine-211 Conjugated to Anti-HER2/neu Diabodies , 2008, Clinical Cancer Research.
[14] E. M. Link,et al. 211At-methylene blue for targeted radiotherapy of human melanoma xenografts: treatment of micrometastases. , 1990, Cancer research.
[15] M. Zalutsky,et al. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. , 2000, Current pharmaceutical design.
[16] G. Henriksen,et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.
[17] I. Ghobrial,et al. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma. , 2004, Oncology.
[18] M. Brechbiel,et al. Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy. , 2013, Cancer biotherapy & radiopharmaceuticals.
[19] H. Wolterbeek,et al. A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters? , 2015, Pharmaceuticals.
[20] S. Larson,et al. Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Albertsson,et al. Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials , 2015, Scientific Reports.
[22] D. Scheinberg,et al. Recovery of Bi-213 from an Ac-225 Cow: Application to the Radiolabeling of Antibodies with Bi-213 , 1995 .
[23] I. Vergote,et al. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors , 2015, Therapeutic advances in medical oncology.
[24] W. Oyen,et al. Antibody-guided radiation therapy of cancer , 2005, Cancer and Metastasis Reviews.
[25] A. Bosserhoff,et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma , 2007, Cancer biology & therapy.
[26] C. Vanhove,et al. SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.
[27] M. Brechbiel,et al. Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer , 2007, Cancer biology & therapy.
[28] Giovanni Paganelli,et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] Scott C. Williams,et al. Radioimmunotherapy of Non-Hodgkin’s Lymphoma: From the ‘Magic Bullets’ to ‘Radioactive Magic Bullets’ , 2011, The Yale journal of biology and medicine.
[30] M. Briel,et al. Somatostatin Receptor–Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial , 2015, The Journal of Nuclear Medicine.
[31] S. Nilsson,et al. High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.
[32] S. Muyldermans,et al. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target , 2013, Expert opinion on biological therapy.
[33] Raffaella Barone,et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. , 2006, Seminars in nuclear medicine.
[34] C. Friesen,et al. Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells , 2013, Oncotarget.
[35] D. Bigner,et al. High-Level Production of α-Particle–Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use , 2001 .
[36] J. Barbet,et al. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model , 2015, Front. Med..
[37] R. Schibli,et al. Prospects in Folate Receptor-Targeted Radionuclide Therapy , 2013, Front. Oncol..
[38] D. Scheinberg,et al. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. , 2008, Advanced drug delivery reviews.
[39] S. Muyldermans,et al. Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody , 2014, Theranostics.
[40] S. Muyldermans,et al. Molecular Imaging with Macrophage CRIg-Targeting Nanobodies for Early and Preclinical Diagnosis in a Mouse Model of Rheumatoid Arthritis , 2014, The Journal of Nuclear Medicine.
[41] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[42] P. De Baetselier,et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. , 2012, Immunobiology.
[43] M. Boyd,et al. Radiation quality‐dependent bystander effects elicited by targeted radionuclides , 2008, The Journal of pharmacy and pharmacology.
[44] B. Oborn,et al. Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. , 2012, Medical physics.
[45] Julien Torgue,et al. Dose Escalation and Dosimetry of First-in-Human α Radioimmunotherapy with 212Pb-TCMC-Trastuzumab , 2014, The Journal of Nuclear Medicine.
[46] F. Grünwald,et al. Update on recent developments in the therapy of differentiated thyroid cancer. , 2010, Seminars in nuclear medicine.
[47] L. Jacobsson,et al. The α-Camera: A Quantitative Digital Autoradiography Technique Using a Charge-Coupled Device for Ex Vivo High-Resolution Bioimaging of α-Particles , 2010, The Journal of Nuclear Medicine.
[48] M. Zalutsky,et al. Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 3: α-Particle–Induced Radiolytic Effects on the Chemical Behavior of 211At , 2007, Journal of Nuclear Medicine.
[49] Yong Li,et al. Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer , 2005, Clinical & Experimental Metastasis.
[50] C. Vanhove,et al. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma , 2016, The Journal of Nuclear Medicine.
[51] D. Scheinberg,et al. Design and synthesis of 225Ac radioimmunopharmaceuticals. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[52] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[53] L. Jacobsson,et al. Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.
[54] Ø. Bruland,et al. Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice. , 2013, Current radiopharmaceuticals.
[55] D. Scheinberg,et al. The Promise of Targeted α-Particle Therapy , 2005 .
[56] Yong Li,et al. Intralesional targeted alpha therapy for metastatic melanoma , 2005, Cancer biology & therapy.
[57] B. Wessels,et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.
[58] O. Sartor,et al. Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects. , 2015, Oncology.
[59] S. Larson,et al. Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.
[60] J. Humm,et al. Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.
[61] S. Shen,et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. , 2014, Cancer biotherapy & radiopharmaceuticals.
[62] H. Lundqvist,et al. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. , 2007, Oncology reports.
[63] N. Bander,et al. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen , 2002, Prostate Cancer and Prostatic Diseases.
[64] Fredrik Y Frejd,et al. Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.
[65] G. Goozée,et al. In vitro and preclinical studies of targeted alpha therapy (TAT) for colorectal cancer , 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[66] S. Muyldermans,et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies , 2014, Leukemia.
[67] S. Muyldermans,et al. In Vitro Analysis and In Vivo Tumor Targeting of a Humanized, Grafted Nanobody in Mice Using Pinhole SPECT/Micro-CT , 2010, Journal of Nuclear Medicine.
[68] J. Dahle,et al. Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab , 2012, PloS one.
[69] Barry J. Allen,et al. Microdosimetry for Targeted Alpha Therapy of Cancer , 2012, Comput. Math. Methods Medicine.
[70] R. Coleman,et al. Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6 , 2007, Journal of Nuclear Medicine.
[71] S. Muyldermans,et al. Naturally occurring antibodies devoid of light chains , 1993, Nature.
[72] M. Zalutsky,et al. Astatine-211: production and availability. , 2011, Current radiopharmaceuticals.
[73] J. Nesland,et al. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[74] H. Lyerly,et al. Improved Tumor Targeting of Anti-HER2 Nanobody Through N-Succinimidyl 4-Guanidinomethyl-3-Iodobenzoate Radiolabeling , 2014, The Journal of Nuclear Medicine.
[75] Franz Buchegger,et al. Auger radiation targeted into DNA: a therapy perspective , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[76] L. Kvols,et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. , 2002, Seminars in nuclear medicine.
[77] L. Jacobsson,et al. The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study. , 2000, Acta oncologica.
[78] B. Allen,et al. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer , 2007, Physics in medicine and biology.
[79] D. Scheinberg,et al. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. , 2003, Cancer research.
[80] M. Brechbiel,et al. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A”-C595 , 2005, Cancer biology & therapy.
[81] D. Bigner,et al. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. , 1999, Nuclear medicine and biology.
[82] S. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.
[83] M. Pimpinella,et al. Oncogenic bystander radiation effects in Patched heterozygous mouse cerebellum , 2008, Proceedings of the National Academy of Sciences.
[84] S. Fosså,et al. First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.
[85] Yong Li,et al. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells. , 2005, Investigative ophthalmology & visual science.
[86] I. Navarro-Teulon,et al. Clinical radioimmunotherapy—the role of radiobiology , 2011, Nature Reviews Clinical Oncology.
[87] D. Scheinberg,et al. Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer , 2014, The Journal of Nuclear Medicine.
[88] B. Allen,et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. , 2011, Immunotherapy.
[89] M. Zalutsky,et al. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[90] J. Roeske,et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[91] W A Volkert,et al. Therapeutic radionuclides: production and decay property considerations. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[92] S. Larson,et al. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[93] J. Humm,et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody , 2011, Physics in medicine and biology.
[94] M. Ranson,et al. Preclinical studies of targeted α therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2 , 2003, British Journal of Cancer.
[95] J. Pagel,et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. , 2010, Blood.
[96] E. Estey,et al. Phase I Trial Of The Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) In Combination With Low-Dose Cytarabine (LDAC) For Older Patients With Untreated Acute Myeloid Leukemia (AML) , 2013 .
[97] J. Humm,et al. Targeted α particle immunotherapy for myeloid leukemia , 2002 .
[98] D. Scheinberg,et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[99] A. Mintz,et al. Molecular targeted α-particle therapy for oncologic applications. , 2014, AJR. American journal of roentgenology.
[100] A. Wolf,et al. Astatine-211--tellurium radiocolloid cures experimental malignant ascites. , 1981, Science.
[101] M. Zalutsky,et al. 5-[211At]Astato-2′-deoxyuridine, an α-Particle-emitting Endoradiotherapeutic Agent Undergoing DNA Incorporation , 1996 .
[102] A. Perkins,et al. Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model , 2008, Cancer biology & therapy.
[103] A. Merlo,et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[104] T. Stokke,et al. Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th. , 2007, Cancer biotherapy & radiopharmaceuticals.
[105] D. Kletsas,et al. The role of oxidative DNA damage in radiation induced bystander effect. , 2015, Cancer letters.
[106] L. Hooft,et al. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. , 2016, European urology.
[107] M. Zalutsky,et al. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[108] S. Fosså,et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[109] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[110] R. Schiffelers,et al. Downregulation of EGFR by a novel multivalent nanobody-liposome platform. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[111] L. Jacobsson,et al. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. , 2006, Nuclear medicine and biology.
[112] C. Vanhove,et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. , 2011, Contrast media & molecular imaging.
[113] M. Zalutsky,et al. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. , 1998, Nuclear medicine and biology.
[114] L. Chappell,et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. , 2000, Nuclear medicine and biology.
[115] C. Apostolidis,et al. Cyclotron production of Ac-225 for targeted alpha therapy. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.